Pasithea Therapeutics (KTTA) Operating Leases (2022 - 2024)
Historic Operating Leases for Pasithea Therapeutics (KTTA) over the last 3 years, with Q1 2024 value amounting to $32989.0.
- Pasithea Therapeutics' Operating Leases fell 9291.25% to $32989.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $32989.0, marking a year-over-year decrease of 9291.25%. This contributed to the annual value of $81680.0 for FY2023, which is 7625.73% down from last year.
- Pasithea Therapeutics' Operating Leases amounted to $32989.0 in Q1 2024, which was down 9291.25% from $81680.0 recorded in Q4 2023.
- Over the past 5 years, Pasithea Therapeutics' Operating Leases peaked at $724386.0 during Q3 2022, and registered a low of $32989.0 during Q1 2024.
- Over the past 3 years, Pasithea Therapeutics' median Operating Leases value was $371766.5 (recorded in 2022), while the average stood at $352227.9.
- In the last 5 years, Pasithea Therapeutics' Operating Leases surged by 1884.6% in 2023 and then tumbled by 9291.25% in 2024.
- Over the past 3 years, Pasithea Therapeutics' Operating Leases (Quarter) stood at $344021.0 in 2022, then tumbled by 76.26% to $81680.0 in 2023, then crashed by 59.61% to $32989.0 in 2024.
- Its last three reported values are $32989.0 in Q1 2024, $81680.0 for Q4 2023, and $385288.0 during Q3 2023.